Insulet CORP 8-K filings

Insulet Corporation reported preliminary second-quarter revenue of $488 million, a 23% increase year-over-year, and raised its full-year 2024 Omnipod revenue outlook.

Insulet Corporation successfully held its 2024 Annual Meeting, electing directors, approving executive compensation, and ratifying its auditor.

Insulet Corporation and NXP USA, Inc. have extended their existing supply agreement, clarifying force majeure events and amending pricing terms.

Insulet Corporation announced a 23% year-over-year revenue increase for the first quarter of 2024, exceeding expectations and leading to raised full-year revenue and operating margin guidance.

Insulet Corporation has appointed Ana Maria Chadwick as its new Executive Vice President, Chief Financial Officer, and Treasurer, effective April 22, 2024.

Insulet Corporation's Talent and Compensation Committee approved revisions to its equity agreements for fiscal year 2024, incorporating updates related to privacy, compensation recoupment, and international compliance.

Insulet Corporation announced a 30% increase in full-year 2023 revenue and a 38% increase in fourth-quarter revenue, driven by strong demand for its Omnipod insulin delivery system.

Insulet Corporation has entered into an amendment to its credit agreement, replacing existing term loans with new ones at reduced interest rates and also lowering rates on its revolving credit facility.

Insulet Corporation has appointed Flavia Pease and Timothy Stonesifer to its Board of Directors, while Shacey Petrovic and Corinne Nevinny will retire at the 2024 Annual Meeting.